Bemcentinib/Pembrolizumab Combo Active in Chemo-Refractory NSCLC
September 9th 2019The first-in-class AXL inhibitor bemcentinib (BGB324) demonstrated activity in combination with the PD-1 inhibitor pembrolizumab in patients with advanced non–small cell lung cancer who had no prior exposure to immunotherapy.
Read More
Talking Tumors: Leveraging Immunotherapy in Nonsquamous NSCLC
August 14th 2019Stephen V. Liu, MD, of Medstar Georgetown University Medical Center, and Konstantinos Arnaoutakis, MD, of Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences, discuss the results of a Twitter poll regarding the use of single-agent immunotherapy versus combination chemotherapy and immunotherapy in a patient with nonsquamous non–small cell lung cancer and to shed light on the data that support each intended treatment choice.
Read More
Saul Priceman, PhD, City of Hope assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a chimeric antigen receptor T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.
Read More
Pelotonia Institute for Immuno-Oncology Launched at Ohio State with $102,265,000 Investment
August 2nd 2019The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute announced formation of the Pelotonia Institute for Immuno-Oncology, a comprehensive bench-to-bedside research initiative focused on harnessing the body’s immune system to fight cancer at all levels—from prevention to treatment and survivorship.
Read More
Siteman Cancer Center Awarded $7.8 Million to Expand Clinical Trials Access
August 2nd 2019Physicians at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have been awarded a $7.8 million grant from the National Cancer Institute to play a leading role in designing, conducting and enrolling patients in clinical trials through the NCI
Read More
Patrick I. Borgen, MD: From the Wild West of Breast Cancer Research to Chasing Cure
July 24th 2019Patrick I. Borgen, MD, of Maimonides Medical Center, shares his live-by mottos as a breast cancer surgeon, a patient who defined his career, and what fuels his passion to fight breast cancer and remove opioid use after surgery.
Read More
UT Southwestern Researchers Find Evidence a Cancer Drug May Be Extended to Many More Patients
July 24th 2019A new molecular mechanism discovered by UT Southwestern researchers indicates that drugs currently used to treat less than 10 percent of breast cancer patients could have broader effectiveness in treating all cancers where the drugs are used, including ovarian and prostate cancers.
Read More
Statistics Show Increase in US Cancer Survivors
July 20th 2019The growth and aging of the population combined with advances in the early detection and treatment of cancer have resulted in a growing population of survivors across the nation, according to a study from the American Cancer Society and the National Cancer Institute.
Read More
Hairy Cell Leukemia: A Review of Epidemiology and Disease Presentation
July 11th 2019Despite the significant progress that has been made regarding the incidence, risk factors, and symptoms of hairy cell leukemia, diagnosis remains a challenge, due in part to the low incidence of the disease.
Read More